What price per share was used for the Emergent BioSolutions (EBS) tax-withholding shares?

The filing shows a price of $8.00 per share for the 3,964 shares withheld. This figure is used to calculate the value of stock delivered to satisfy the tax obligation tied to the vesting and settlement of the executive’s restricted stock units.

Emergent BioSolutions (EBS) CFO has 3,964 RSU shares withheld for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported a routine tax-related share disposition. On the reported date, 3,964 shares of common stock were withheld at $8.00 per share to cover taxes tied to the vesting and settlement of restricted stock units, rather than being sold on the open market. After this withholding, Lindahl directly held 374,083 shares of common stock, indicating he retains a substantial equity position in the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LINDAHL RICHARD S

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	3,964	$8.00	$32K

Holdings After Transaction: Common Stock — 374,083 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares withheld for taxes: 3,964 shares Withholding price: $8.00 per share Shares held after transaction: 374,083 shares +1 more

4 metrics

Shares withheld for taxes 3,964 shares Withheld to pay taxes on RSU vesting

Withholding price $8.00 per share Value used for tax-withholding disposition

Shares held after transaction 374,083 shares Direct holdings following tax withholding

Transaction type Tax-withholding disposition (Code F) Payment of tax liability by delivering securities

Key Terms

restricted stock units, tax-withholding disposition, Common Stock, transaction code F

4 terms

restricted stock units financial

"vesting and settlement of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code F financial

""transaction_code": "F""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 03:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last)

(First)

(Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG

MARYLAND

20879

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		F		3,964⁽¹⁾	D	$8	374,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Richard S. Lindahl	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Emergent BioSolutions (EBS) CFO Richard Lindahl report in this Form 4?

Richard Lindahl reported a tax-related disposition of 3,964 Emergent BioSolutions shares. The shares were withheld at $8.00 per share to satisfy taxes from restricted stock unit vesting, rather than sold in the open market, and are part of routine compensation processing.

Was the Emergent BioSolutions (EBS) CFO’s Form 4 transaction an open-market stock sale?

No, the transaction was not an open-market sale. The 3,964 shares were withheld by the company to pay taxes associated with the vesting and settlement of restricted stock units, according to the footnote, which characterizes it as a tax-withholding event, not discretionary selling.

How many Emergent BioSolutions (EBS) shares does the CFO hold after this transaction?

After the tax-withholding transaction, Richard Lindahl directly holds 374,083 shares of Emergent BioSolutions common stock. This figure, disclosed in the filing, reflects his remaining equity stake following the withholding of 3,964 shares for tax obligations on vested restricted stock units.

What does transaction code F mean in the Emergent BioSolutions (EBS) Form 4?

Transaction code F indicates a disposition to pay an exercise price or tax liability by delivering securities. In this case, 3,964 Emergent BioSolutions shares were withheld to cover taxes on restricted stock unit vesting, rather than being sold at the holder’s discretion in the open market.